Rituximab Vasculitis Maintenance Study

NCT01697267 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

188

Enrollment

OTHER

Sponsor class

Conditions

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Microscopic Polyangiitis
Wegener Granulomatosis

Interventions

BIOLOGICAL: Rituximab
DRUG: Azathioprine

Sponsor

Cambridge University Hospitals NHS Foundation Trust

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]